PHAR (Pharming Group NV) רווח נקי

This daily price chart on the GURU.Markets platform illustrates the performance of Pharming Group N.V. (PHAR), which develops unique therapies for rare immune pathologies and generates high profits due to a lack of competition. The current metric stands at 0.02, supported by the global market expansion of its flagship drugs. The company's capital is formed through insurance payments for the lifelong treatment of patients with hereditary angioedema.

Investors verify issuer reliability by comparing cash flows to market capitalization. This metric measures daily net profit in the US market, separating the fundamental trend from volatility. By analyzing the consolidated earnings of Pharming Group N.V. (PHAR), one can assess the risk of overpaying for current yields. Growth in this indicator confirms the efficiency of bottling line robotization and bioreactor automation at Pharming Group N.V. (PHAR). The stable trajectory of this chart indicates the successful scaling of drug production.